MTOR and lymphoma: Lymphomas resistant to proteasome inhibitors show increased expression in BCR and activation of the BCR signaling pathway enhances the activity of SFK, especially LYN, and downstream kinases PI3K/AKT/mTOR in proteasome inhibitor-resistant lymphoma cells.